X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.
Lead Product(s): Recombinant Protein Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Laboratorios HIPRA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein.
Lead Product(s): CTI-1601
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Larimar Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p<0.0001).
Lead Product(s): Nedosiran
Therapeutic Area: Genetic Disease Product Name: DCR-PHXC
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Dicerna Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein.
Lead Product(s): CTI-1601
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Larimar Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021
Details:
Data show that repeated subcutaneous administration of CTI-1601 resulted in dose-dependent increases in frataxin (FXN) levels from baseline compared to placebo controls.
Lead Product(s): CTI-1601
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Larimar Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Details:
Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin.
Lead Product(s): Otenaproxesul
Therapeutic Area: Musculoskeletal Product Name: ATB-346
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Antibe Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
Under the terms of the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical program and write the required protocol.
Lead Product(s): Cannabidiol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: PreveCeutical Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
